Legal & General Group PLC Cytosorbents Corp Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.39 - $2.46 $4,420 - $7,822	-3,180 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$1.76 - $3.22 $2,277 - $4,166	-1,294 Reduced 28.92%	3,180 $7,000
Q1 2022 May 16, 2022	BUY	$2.88 - $4.23 $849 - $1,247	295 Added 7.06%	4,474 $14,000
Q3 2021 Nov 15, 2021	SELL	$7.0 - $9.71 $1,232 - $1,708	-176 Reduced 4.04%	4,179 $34,000
Q2 2021 Aug 12, 2021	SELL	$7.55 - $9.42 $2,431 - $3,033	-322 Reduced 6.88%	4,355 $33,000

Q1 2021 May 17, 2021	SELL	$8.23 - $11.48 $1,720 - $2,399	-209 Reduced 4.28%	4,677 $41,000
Q3 2020 Nov 13, 2020	SELL	$7.37 - $11.54 $5,932 - $9,289	-805 Reduced 14.15%	4,886 $39,000
Q2 2020 Aug 14, 2020	BUY	$6.28 - $10.59 $4,910 - $8,281	782 Added 15.93%	5,691 $56,000
Q1 2020 May 14, 2020	SELL	$3.77 - $7.73 $4,938 - $10,126	-1,310 Reduced 21.06%	4,909 $34,000
Q4 2019 Feb 13, 2020	BUY	$3.61 - $5.22 $4,317 - $6,243	1,196 Added 23.81%	6,219 $24,000
Q4 2018 Feb 15, 2019	BUY	$7.05 - $12.64 $5,555 - $9,960	788 Added 18.61%	5,023 $41,000
Q2 2018 Aug 10, 2018	BUY	$6.9 - $12.35 $29,221 - $52,302	4,235 New	4,235 $48,000

17.8M

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $39.7M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.